MedTrace Logo

Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)

NCT07753603 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2026-08-11

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease (TED).

Conditions

  • Thyroid Eye Disease, TED
  • Graves Orbitopathy

Interventions

DRUG

linsitinib

150 mg linsitinib is taken twice daily by mouth for 24 weeks

DRUG

Placebo

0 mg placebo taken twice daily by mouth for 24 weeks

Sponsors & Collaborators

  • Sling Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-04
Primary Completion
2028-06-30
Completion
2030-06-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07753603 on ClinicalTrials.gov